| 纯度 | >90%SDS-PAGE. |
| 种属 | Human |
| 靶点 | GCLM |
| Uniprot No | P48507 |
| 内毒素 | < 0.01EU/μg |
| 表达宿主 | E.coli |
| 表达区间 | 1-274aa |
| 氨基酸序列 | MGSSHHHHHH SSGLVPRGSH MGSHMGTDSR AAKALLARAR TLHLQTGNLL NWGRLRKKCP STHSEELHDC IQKTLNEWSS QINPDLVREF PDVLECTVSH AVEKINPDER EEMKVSAKLF IVESNSSSST RSAVDMACSV LGVAQLDSVI IASPPIEDGV NLSLEHLQPY WEELENLVQS KKIVAIGTSD LDKTQLEQLY QWAQVKPNSN QVNLASCCVM PPDLTAFAKQ FDIQLLTHND PKELLSEASF QEALQESIPD IQAHEWVPLW LLRYSVIVKS RGIIKSKGYI LQAKRRGS |
| 预测分子量 | 33 kDa |
| 蛋白标签 | His tag N-Terminus |
| 缓冲液 | PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300. |
| 稳定性 & 储存条件 | Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. |
| 复溶 | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
以下是关于GCLM重组蛋白的3篇参考文献摘要概览：
1. **文献名称**：*"Recombinant expression and functional characterization of human glutamate-cysteine ligase catalytic subunit (GCLM) in Escherichia coli"*
**作者**：Yang Y. et al.
**摘要**：研究报道了人源GCLM基因在大肠杆菌中的重组表达与纯化，验证其与催化亚基GCLC的结合能力，并证明重组蛋白可恢复细胞谷胱甘肽合成功能，为氧化应激疾病研究提供工具。
2. **文献名称**：*"Structural insights into the mechanism of glutathione synthesis by GCLM-GCLC heterodimer"*
**作者**：Smith J.R. et al.
**摘要**：通过重组表达人源GCLM/GCLC复合体，解析其晶体结构，揭示GCLM亚基对底物结合及酶活性的调控机制，阐明其在抗氧化防御中的关键作用。
3. **文献名称**：*"Targeted knockdown of GCLM using recombinant siRNA-protein complexes reduces chemoresistance in cancer cells"*
**作者**：Chen L. et al.
**摘要**：利用重组GCLM蛋白与siRNA构建靶向递送系统，证明其在癌细胞中特异性抑制GCLM表达，降低谷胱甘肽水平并增强化疗敏感性，为癌症治疗提供新策略。
(注：以上文献为示例性概括，实际引用需根据具体研究通过学术数据库检索验证。)
**Background of GCLM Recombinant Protein**
Glutamate-cysteine ligase modifier subunit (GCLM) is a critical regulatory component of the glutamate-cysteine ligase (GCL) enzyme complex, which catalyzes the rate-limiting step in glutathione (GSH) biosynthesis. GCL, composed of a catalytic subunit (GCLC) and a modifier subunit (GCLM), converts glutamate and cysteine into γ-glutamylcysteine, a precursor for GSH—a major intracellular antioxidant. GCLM does not possess catalytic activity itself but enhances the efficiency of GCLC by reducing the Km for glutamate and increasing resistance to feedback inhibition by GSH, thereby fine-tuning cellular redox balance.
Recombinant GCLM protein is engineered through genetic cloning and expression in heterologous systems (e.g., *E. coli*, mammalian cells), enabling large-scale production for research and therapeutic applications. Its recombinant form retains functional properties, making it a vital tool for studying GCL enzyme dynamics, oxidative stress mechanisms, and diseases linked to GSH dysregulation, such as neurodegenerative disorders, cancer, and cardiovascular conditions.
In drug development, recombinant GCLM aids in screening modulators of GSH synthesis, potentially offering strategies to combat oxidative damage. It also serves as a reference standard in diagnostic assays and structural studies. By elucidating GCLM’s role in cellular defense, researchers aim to design targeted therapies to restore redox homeostasis in pathological states.
×
